vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Orange County Bancorp, Inc. (OBT). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $33.0M, roughly 1.1× Orange County Bancorp, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -3.7%, a 41.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 20.6%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 14.3%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.
GYRE vs OBT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $33.0M |
| Net Profit | $-1.4M | $12.4M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 41.4% |
| Net Margin | -3.7% | 37.6% |
| Revenue YoY | 33.4% | 20.6% |
| Net Profit YoY | -340.1% | 73.5% |
| EPS (diluted) | $-0.01 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $33.0M | ||
| Q3 25 | $30.6M | $33.7M | ||
| Q2 25 | $26.8M | $32.5M | ||
| Q1 25 | $22.1M | $28.0M | ||
| Q4 24 | $27.9M | $27.4M | ||
| Q3 24 | $25.5M | $27.1M | ||
| Q2 24 | $25.2M | $27.9M | ||
| Q1 24 | $27.2M | $25.3M |
| Q4 25 | $-1.4M | $12.4M | ||
| Q3 25 | $5.9M | $10.0M | ||
| Q2 25 | $1.6M | $10.5M | ||
| Q1 25 | $3.7M | $8.7M | ||
| Q4 24 | $569.0K | $7.2M | ||
| Q3 24 | $2.9M | $3.2M | ||
| Q2 24 | $4.5M | $8.2M | ||
| Q1 24 | $9.9M | $9.3M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 41.4% | ||
| Q3 25 | 22.7% | 38.6% | ||
| Q2 25 | 8.1% | 41.9% | ||
| Q1 25 | 10.3% | 40.3% | ||
| Q4 24 | 2.4% | 32.8% | ||
| Q3 24 | 16.6% | 14.8% | ||
| Q2 24 | 12.7% | 36.6% | ||
| Q1 24 | 29.7% | 45.9% |
| Q4 25 | -3.7% | 37.6% | ||
| Q3 25 | 19.4% | 29.7% | ||
| Q2 25 | 5.9% | 32.2% | ||
| Q1 25 | 16.9% | 31.1% | ||
| Q4 24 | 2.0% | 26.2% | ||
| Q3 24 | 11.2% | 11.8% | ||
| Q2 24 | 18.0% | 29.4% | ||
| Q1 24 | 36.6% | 36.7% |
| Q4 25 | $-0.01 | $0.94 | ||
| Q3 25 | $0.03 | $0.75 | ||
| Q2 25 | $0.00 | $0.87 | ||
| Q1 25 | $0.00 | $0.77 | ||
| Q4 24 | $0.00 | $0.64 | ||
| Q3 24 | $0.01 | $0.28 | ||
| Q2 24 | $0.01 | $0.73 | ||
| Q1 24 | $0.03 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $284.4M |
| Total Assets | $166.1M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $37.4M | — |
| Q4 25 | $106.0M | $284.4M | ||
| Q3 25 | $101.9M | $270.1M | ||
| Q2 25 | $92.0M | $252.6M | ||
| Q1 25 | $68.1M | $201.3M | ||
| Q4 24 | $63.3M | $185.5M | ||
| Q3 24 | $63.2M | $193.1M | ||
| Q2 24 | $60.4M | $177.5M | ||
| Q1 24 | $56.6M | $168.7M |
| Q4 25 | $166.1M | $2.7B | ||
| Q3 25 | $159.4M | $2.6B | ||
| Q2 25 | $152.6M | $2.6B | ||
| Q1 25 | $129.8M | $2.6B | ||
| Q4 24 | $125.4M | $2.5B | ||
| Q3 24 | $125.2M | $2.5B | ||
| Q2 24 | $120.9M | $2.5B | ||
| Q1 24 | $122.0M | $2.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $43.8M |
| Free Cash FlowOCF − Capex | $-5.8M | $41.3M |
| FCF MarginFCF / Revenue | -15.5% | 125.1% |
| Capex IntensityCapex / Revenue | 0.4% | 7.6% |
| Cash ConversionOCF / Net Profit | — | 3.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $69.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $43.8M | ||
| Q3 25 | $4.7M | $30.2M | ||
| Q2 25 | $2.1M | $-5.0M | ||
| Q1 25 | $-129.0K | $4.8M | ||
| Q4 24 | $-2.8M | $34.6M | ||
| Q3 24 | $1.7M | $10.2M | ||
| Q2 24 | $-5.5M | $9.3M | ||
| Q1 24 | $2.9M | $2.3M |
| Q4 25 | $-5.8M | $41.3M | ||
| Q3 25 | $4.0M | $29.6M | ||
| Q2 25 | $1.8M | $-5.7M | ||
| Q1 25 | $-251.0K | $4.3M | ||
| Q4 24 | $-2.8M | $32.9M | ||
| Q3 24 | $1.0M | $10.0M | ||
| Q2 24 | $-6.9M | $9.2M | ||
| Q1 24 | $2.7M | $2.0M |
| Q4 25 | -15.5% | 125.1% | ||
| Q3 25 | 13.1% | 87.8% | ||
| Q2 25 | 6.8% | -17.5% | ||
| Q1 25 | -1.1% | 15.5% | ||
| Q4 24 | -10.1% | 120.0% | ||
| Q3 24 | 4.1% | 36.7% | ||
| Q2 24 | -27.5% | 32.8% | ||
| Q1 24 | 9.8% | 7.9% |
| Q4 25 | 0.4% | 7.6% | ||
| Q3 25 | 2.2% | 1.8% | ||
| Q2 25 | 1.0% | 2.3% | ||
| Q1 25 | 0.6% | 1.8% | ||
| Q4 24 | 0.2% | 6.3% | ||
| Q3 24 | 2.7% | 1.1% | ||
| Q2 24 | 5.8% | 0.4% | ||
| Q1 24 | 0.9% | 1.0% |
| Q4 25 | — | 3.53× | ||
| Q3 25 | 0.79× | 3.01× | ||
| Q2 25 | 1.32× | -0.47× | ||
| Q1 25 | -0.03× | 0.56× | ||
| Q4 24 | -4.85× | 4.83× | ||
| Q3 24 | 0.60× | 3.19× | ||
| Q2 24 | -1.21× | 1.13× | ||
| Q1 24 | 0.29× | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
